Skip to main content

Search
Profile

Douglas S. Hawkins, MD

|
Douglas S. Hawkins, MD

Hematology-Oncology

On staff since February 1996

Children's Title: Associate Division Chief, Hematology/Oncology

Academic Title: Professor of Pediatrics, UW School of Medicine

Research Center: Center for Clinical and Translational Research

"I feel exceptionally fortunate to work with some of the smartest people I know. Every day brings new opportunities to learn from my colleagues, patients and families. By the nature of our work in Hematology/Oncology, there is never a question about the importance of what we do every day. I am continually impressed that we have the opportunity to change the lives of children and young adults for the better, both with good clinical care and by leading clinical and translational research efforts. My hope is that the clinical research we do today will lead to more effective treatments with fewer side effects for children and young adults in the future."

Recommendations

KellySeattle, WA07.09.13
Our sons life was saved by Dr. Hawkins and his incredible team. From the confusion and shock of the initial diagnosis to end of treatment celebration, Dr. Hawkins not only walked by our son's side every step of the way, he personally invested in our entire family. Dr. Hawkins is equal parts honest, courageous, brilliant, and compassionate. Dr. Hawkins and his team are an inspiration, and our family is eternally grateful for all that they do!
RahilKent, WA10.19.12
Dr. Hawkins is a professional, kind and caring doctor with a large expertise in treating childhood cancer. Upon our orientation at Children's, he was the key person that explained the medicines, treatment plan, schedule and expectations. He explained differences in treatment plans in Europe and North America. He presented our scans, biopsy and test results making sure that we understood everything. He has done a good job and our son is now cured of cancer. Thank you Dr. Hawkins and the expert staff at Seattle Children's!
HeatherSnoqualmie, WA09.25.12
Dr. Hawkins and his incredible team saved out daughters life. Dr. Hawkins had the insight to look past the original diagnosis given to our daughter. She was diagnosed with TEC at 15 months with a HCT of 7. This was not life sustaining. He and his team consulted, worked, planned and communitcated with each other and our family to come up with the best course of treatment. I cant thank Dr. Hawkins and Seattle Children's enough. They preform miracles everyday!
janicewenatchee, wa.02.13.12
Dr. Hawkins works around the clock to give our children the best care. I am happy to say my son is a bone cancer survivor. I appreciated how Dr. Hawkins worked to make sure the side affects from the chemo where addressed as well as its progress. Thank you so much, Janice B.
elcekent,washinton09.28.11
Dr. Hawkins saved my daughters life,who was diagnosed with stage 4 alveolar rhabdomyosarcoma last year.My daughter is cancer free for almost three months now because of Dr. Hawkins and his team.God bless them.God is Good.
Beckyseattle ,wa06.16.11
I was a distraught parent when my daughter was diagnosed at 15 with Hodgkin's lymphoma. he spent the time to make me feel at ease and encouraged me to participate in her care . i didn't have a clue what i should do . he made me feel comfortable to ask a lot of questions, and he answered with reassurance and calmness . He worked closely with me as a parent as well as his colleagues to give her the best care she could get. he responded as quickly as possible to all of my phone calls. He is a very humble man for all of his qualifications . there are a lot of people who look up to him , if he only knew how many .... many thanks!! we pray for his continued success!!
LynoraKetchikan, Alaska04.14.11
Five years ago, my 8 1/2 year old son was diagnosed with Hodgkin's Lymphoma. I remember Dr Hawkins looking me right in the eye and saying, "This cancer is very, very, VERY curable." I clung to his words, and today we are celebrating my son's 14th birthday. Thank you Dr. Hawkins, and Children's, for assisting God in our son's healing!
KathleenSeattle, WA03.30.11
If you are seeing Dr. Hawkins, you've likely heard the worst thing you will ever hear: your child has cancer. If that's the case, thank God you're seeing Dr. Hawkins! My son nearly died before he was diagnosed in 1997 at age 2 with Burkitt's Lymphoma. We were so grateful to have Dr. Hawkins on his team. He's honest, clear, compassionate and simply the most knowledgeable physician treating kids today. My son is 16 now, rowing crew and making the honor roll!
camilleseattle washington02.17.11
Dr. Hawkins is my personal Hero! I was two weeks short of dying when he took over. I had stage 4 hodgkins lymphoma I was 15 yrs old. I am now 20 and I have a beautiful son and have been in remisson for 5 yrs now. Thank you Dr. Hawkins!
LynoraKetchikan, Alaska04.14.11
Five years ago, my 8 1/2 year old son was diagnosed with Hodgkin's Lymphoma. I remember Dr Hawkins looking me right in the eye and saying, "This cancer is very, very, VERY curable." I clung to his words, and today we are celebrating my son's 14th birthday. Thank you Dr. Hawkins, and Children's, for assisting God in our son's healing!
TammyMaple Valley, WA12.10.10
Dr. Doug Hawkins and Dr. Lawrence Cooper diagnosed our son Eric as a Lg Cell Lymphoma patient in early 1997 when he was 10. Eric recently had his 24th Birthday, THANKS TO THEIR KNOWLEDGE AND CARE. He is a SURVIVOR!! Thank you to them and all the wonderful nurses that made that hard time bearable. Sincerely, Eric's Mom & Dad
Recommend Dr. Douglas Hawkins

Overview

Board Certification(s)
Pediatric Hematology-Oncology
Medical/Professional School
Harvard Medical School, Boston
Residency
Pediatrics, University of Washington, Seattle
Clinical Interests

Sarcomas, New therapy

Research Description

My clinical research is particularly focused in the treatment of pediatric sarcomas. I am the Children's Oncology Group (COG) chair of the Soft Tissue Sarcoma Committee, which designs and conducts all national studies in pediatric soft tissue sarcomas, including rhabdomyosarcoma. I am the COG chair of two clinical trials, one for Ewing sarcoma and another for rhabdomyosarcoma, and the vice chair of three other COG clinical trials. I am working collaboratively on a pharmacogenomic study investigating cyclophospharmide metabolism and toxicity, both locally and as part of two COG studies, and on the use of FDG PET to assess response and guide treatment in pediatric sarcomas.

Research Focus Area

Cancer

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
SEATTLE MAGAZINE TOP DOCTOR - 2014Seattle Magazine 2014
Seattle Magazine Top Doctor - 2013Seattle Magazine 2013
Seattle's Top DocSeattle Met Magazine 2013
Seattle Magazine Top Doctor - 2012Seattle Magazine Top Doctor - 2012Seattle Magazine 2012
U.S. News Top DoctorU.S. News and World Report 2012
"Guide to America's Top Pediatricians"Consumer's Research Council of America 2009

Publications

Myogenin, AP2, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
The American journal of surgical pathology , 2014 Mar 10
Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.
European journal of cancer (Oxford, England : 1990) , 2014 Mar: 50(4)816-23
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Cancer discovery , 2014 Feb: 4(2)216-31
Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: A report from the Children's Oncology Group.
Pediatric blood & cancer , 2014 Jan 22
Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children's Oncology Group.
International journal of cancer. Journal international du cancer , 2014 Jan 15: 134(2)431-6
Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.
The Journal of bone and joint surgery. American volume , 2014 Jan 15: 96(2)152-8
Targeting oxidative stress in embryonal rhabdomyosarcoma.
Cancer cell , 2013 Dec 9: 24(6)710-24
The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.
International journal of radiation oncology, biology, physics , 2013 Nov 1: 87(3)512-6
A novel algorithm for simplification of complex gene classifiers in cancer.
Cancer research , 2013 Sep 15: 73(18)5625-32
Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2013 Sep 10: 31(26)3226-32
PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
Pediatric blood & cancer , 2013 Sep: 60(9)1411-7
Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: A report from the children's oncology group.
International journal of cancer. Journal international du cancer , 2013 Jul 3
Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.
Pediatric blood & cancer , 2013 Jul: 60(7)1108-12
An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma.
Pediatric blood & cancer , 2013 Jul: 60(7)1113-7
Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
American journal of clinical pathology , 2013 Jul: 140(1)82-90
Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.
Pediatric blood & cancer , 2013 Jul: 60(7)1108-12
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.
Pediatric blood & cancer , 2013 Jun: 60(6)1001-8
Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group.
Pediatric blood & cancer , 2013 Mar: 60(3)371-6
Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors.
Molecular and cellular biology , 2013 Feb: 33(4)773-84
Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity.
Pediatric blood & cancer , 2013 Feb: 60(2)338-9
18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models.
Pediatric blood & cancer , 2012 Sep: 59(3)485-92
Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.
Pediatric blood & cancer , 2012 Jul 15: 59(1)5-10
The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology , 2012 Jul: 21(7)1012-8
The clinical, research, and social value of autopsy after any cancer death: a perspective from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Cancer , 2012 Jun 15: 118(12)3002-9
Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
International journal of radiation oncology, biology, physics , 2012 Jun 1: 83(2)720-6
Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Cancer , 2012 Feb 15: 118(4)1130-7
Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
Drug metabolism and disposition: the biological fate of chemicals , 2012 Jan: 40(1)54-63
Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology Group.
Pediatric blood & cancer , 2011 Dec 1: 57(6)939-42
Sarcomas gone bad: what to do about recurrent Ewing sarcoma.
Pediatric blood & cancer , 2011 Oct: 57(4)535-6
Ewing sarcoma/primitive neuroectodermal tumor arising from the adrenal gland in an adolescent.
Pediatric blood & cancer , 2011 Oct: 57(4)691-2
Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.
Cancer , 2011 Aug 1: 117(15)3493-501
Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group.
International journal of radiation oncology, biology, physics , 2011 Jul 15: 80(4)1151-7
Minimal residual disease detected prior to hematopoietic cell transplantation.
Pediatric blood & cancer , 2011 Jul 15: 57(1)163-5
Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.
Pediatric blood & cancer , 2011 Jul 15: 57(1)76-83
Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Cancer , 2011 Jun 1: 117(11)2541-50
Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group.
International journal of radiation oncology, biology, physics , 2011 Jun 1: 80(2)333-8
Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group.
International journal of radiation oncology, biology, physics , 2011 May 1: 80(1)206-12
Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Apr 1: 29(10)1304-11
(18)F-FDG PET in sarcoma treatment response imaging.
American journal of nuclear medicine and molecular imaging , 2011: 1(1)47-53
Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the children's oncology group.
Cancer , 2010 Dec 14
Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Oct 20: 28(30)4658-63
Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Oct 10: 28(29)e587-8; author reply e589-90
Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Sep 20: 28(27)4228-32
Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2010 Aug 1: 16(15)4024-30
No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia.
Archives of pediatrics & adolescent medicine , 2010 Mar: 214-7
Malignant progression in two children with multiple osteochondromas.
Sarcoma , 2010: 2010417105
Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2009 Dec 1: 15(23)7361-7
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Nov 1: 27(31)5182-8
Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors.
Pediatric blood & cancer , 2009 Sep: 53(3)375-8
Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Aug 1: 3705-11
[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
Cancer , 2009 Aug 1: 115(15)3519-25
Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Aug 1: 27(22)3705-11
Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma.
The Journal of bone and joint surgery. American volume , 2009 Mar 1: 91(3)604-12
Cerebrospinal fluid cleaved-tau protein and 9-hydroxyoctadecadienoic acid concentrations in pediatric patients with hydrocephalus.
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies , 2008 Sep: 9(5)524-9
COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
Journal of pediatric hematology/oncology , 2008 Jul: 30(7)507-12
Two boys with fragile x syndrome and hepatic tumors.
Journal of pediatric hematology/oncology , 2008 Mar: 30(3)239-41
Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia.
Pediatric blood & cancer , 2008 Jan: 50(1)189
Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Pediatric blood & cancer , 2008 Jan: 50(1)33-6
Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
European journal of cancer (Oxford, England : 1990) , 2007 Apr: 43(6)1045-50
Pediatric intradural extramedullary synovial sarcoma: case report.
Neurosurgery , 2006 Dec: E1339; discussion E1339
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Pediatric blood & cancer , 2006 Nov: 47(6)790-4
Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia.
Cancer , 2006 Sep 15: 107(6)1400-6
Survival of tumor megaprostheses replacements about the knee.
Clinical orthopaedics and related research , 2006 Sep: 45039-45
[18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2005 Dec 1: 23(34)8828-34
Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2005 Nov 15: 11(22)8089-96
Fas expression in lung metastasis from osteosarcoma patients.
Journal of pediatric hematology/oncology , 2005 Nov: 27(11)611-5
Survival after recurrence of Ewing's sarcoma family of tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2005 Jul 1: 23(19)4354-62
Metastatic malignant melanoma presenting as pancytopenia in a three-year-old boy.
Pediatric blood & cancer , 2005 Jul: 45(1)60-3
Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Cancer , 2005 Jan 15: 103(2)339-48
Transatlantic collaboration in pediatric oncology: now is the time.
Journal of pediatric hematology/oncology , 2004 Dec: 26(12)783-4
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Pediatric blood & cancer , 2004 Oct: 571-9
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2004 Aug 15: 5335-41
Influence of age upon Ifosfamide-induced nephrotoxicity.
Pediatric blood & cancer , 2004 May: 42(5)427-32
Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
Cancer , 2004 Mar 15: 100(6)1268-75
Evaluation of early marrow response in childhood aneuploid acute lymphoblastic leukemia: flow cytometric DNA analysis versus standard morphology.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society , 2004 Jan-Feb: 7(1)39-47
Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Cancer , 2003 Dec 1: 98(11)2447-56
Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma.
Journal of pediatric hematology/oncology , 2003 Oct: 25(10)774-9
Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2003 Apr: 286-91
Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.
Journal of pediatric hematology/oncology , 2003 Apr: 25(4)286-91
Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
Medical and pediatric oncology , 2003 Feb: 40(2)93-8
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Cancer , 2002 Sep 15: 1354-65
Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.
Journal of pediatric hematology/oncology , 2002 Aug-Sep: 24(6)440-6
Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
Cancer , 2002 Jun 15: 94(12)3277-84

Presentations

Presentations TitleEventLocationDate
Progress in the treatment of rhabdomyosarcoma: results of the North American strategyEuropean Cancer CongressAmsterdam, NetherlandsSept. 29, 2013
COG approach to identification and introduction of new/targeted therapies in RMS/STSEuropean Paediatric Soft Tissue Sarcoma MeetingParis, FranceMarch 22, 2013
Childrens Oncology Group update on soft tissue sarcoma clinical trialsEuropean Paediatric Soft Tissue Sarcoma MeetingParis, FranceMarch 22, 2013
Rhabdomyosarcoma: How many and how to treatTexas Childrens Cancer CenterHouston, TXFeb. 14, 2013
What children have taught me about rhabdomyosarcomaPediatric Grand Rounds, Childrens Hospital at MontefioreBronx, NYJan. 30, 2013
From Seattle to Sydney: lessons from selected pediatric sarcoma casesPediatric Oncology ConferenceSydney, AustraliaOct. 8, 2012
Childrens Oncology Group update on soft tissue sarcoma clinical trialsInternational Symposium on the Biology and Treatment of the Pediatric Soft Tissue SarcomasPadova, ItalyDec. 6, 2011
Risk stratification and treatment approaches in rhabdomyosarcoma: a comparison of Europe and North AmericaPediatric Oncology Group of OntarioNov. 19, 2010

Research Funding

Grant TitleGrantorAmountAward Date
Molecular Targeting in Non-Rhabdomyosarcoma Soft Tissue SarcomaSt. Baldricks Foundation $$11,380Sept. 1, 2011 - Aug. 31, 1914
Pharmacogenetics of Cyclophosphamide ADRs in ChildrenNIH/NCI $$38,844Sept. 1, 2011 - Aug. 31, 2013
Early Phase Trials and Biologic Specimen Collection at Seattle Childrens HospitalRally Foundation $$88,170July 1, 2011 - June 30, 2012
Children’s Oncology Group- cooperative group trial, Institutional Principal NIH $57,390.00March 1, 2009
Children’s Oncology Group Soft Tissue Sarcoma Committee ChairNIH $23.913.00March 1, 2009
Children’s Oncology Group trial AEWS0331NIH $11,956.00March 1, 2009
Children’s Oncology Group trial AEWS0531NIH $11,956.00March 1, 2009

Primary Office

Seattle Children's
MB.8.501 - Hematology-Oncology
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2106

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options